Join experts from Olink and Novogene for a webinar on proteomics and longitudinal biomarker analysis in chronic lymphocytic leukemia (CLL). The session will introduce Olink Reveal, review the Novogene Olink Reveal workflow, and highlight how protein profiling can be used to study treatment response over time.
Proteomics can add an important layer of biological insight to genomic and clinical data. In this webinar, Griffin Lentsch, Ph.D. of Olink will present an overview of the Olink platform and discuss a longitudinal CLL study that measured around 1,000 plasma proteins across two patient cohorts during BTK inhibitor therapy. Eric Iverson of Novogene will then walk through the Novogene Olink Reveal workflow and explain how the assay is processed and analyzed. The two presentations will show how longitudinal protein data can support biomarker discovery and help characterize response patterns in CLL.
Topics to be discussed in this webinar
- The basic principles behind Olink Reveal and its use in proteomics research.
- How the Novogene Olink Reveal workflow supports sample processing and analysis.
- The benefits of using longitudinal proteomics to track treatment response and identify candidate biomarkers in CLL.